Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tvardi TherapeuticsFRA:69C -15.88%20 Equity-to-Asset is 0.48 as of Jun. 2026, which is 243% above its 10-year median of 0.14. GuruFocus rates FRA:69C with a GF Score™ of 20/100. The stock has 1 warning sign investors should review. Among 1,412 Biotechnology companies, Tvardi Therapeutics ranks worse than 69.05% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Tvardi Therapeutics Equity-to-Asset Related Terms
Tvardi Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Tvardi Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:69C vs PVCT, CLRB, DYAI: Equity-to-Asset Comparison
For the Biotechnology subindustry, Tvardi Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tvardi Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tvardi Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Tvardi Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Tvardi Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tvardi Therapeutics (FRA:69C) has a Equity-to-Asset of 0.48 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Tvardi Therapeutics and its competitors. This is 243% above median its historical median of 0.14. According to the industry distribution chart, Tvardi Therapeutics ranks #975 out of 1412 companies in the Biotechnology industry, placing it in the top 69.1%.
Is Tvardi Therapeutics' Equity-to-Asset too high?
Tvardi Therapeutics' current Equity-to-Asset of 0.48 is 243% above median its 10-year median of 0.14. The Biotechnology industry median Equity-to-Asset is 0.69. Tvardi Therapeutics' value of 0.48 is 30.4% below this industry median. Based on the distribution chart, Tvardi Therapeutics ranks #975 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Tvardi Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Tvardi Therapeutics' Equity-to-Asset compare to PVCT and CLRB?
According to the Biotechnology industry distribution chart, Tvardi Therapeutics ranks #975 out of 1412 companies for Equity-to-Asset. This places Tvardi Therapeutics in the lower half of its industry. The industry median Equity-to-Asset is 0.69. Tvardi Therapeutics' value of 0.48 is 30.4% below this benchmark. While the company's 10-year median is 0.14 vs. the industry median of 0.69, Tvardi Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tvardi Therapeutics's current Equity-to-Asset of 0.48 is 30.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Tvardi Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tvardi Therapeutics's current Equity-to-Asset is 0.48, which is 243% above median its own 10-year median of 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tvardi Therapeutics stock overvalued right now?
Tvardi Therapeutics (FRA:69C) has a current Equity-to-Asset of 0.48. The current Equity-to-Asset is 0.48, which is 243% above median its 10-year median of 0.14 and 30.4% below the Biotechnology industry median of 0.69. Tvardi Therapeutics' overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Tvardi Therapeutics (FRA:69C), the current Equity-to-Asset is 0.48 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
20GF Score
Get the complete analysis for FRA:69C
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:69C has been successfully added to your 
